［Abstract］　Genetic factors play a pivotal role in the occurrence and progression of gynecologic neoplasms. Hereditary gynecological cancer syndromes(HGCS) are cancer susceptibility disorders caused by pathogenic germline mutations, accounting for 5%-10% of all newly diagnosed malignant tumors each year. HGCS are characterized by early onset, multiple primary tumors, familial aggregation, and autosomal dominant inheritance. HGCS not only increase the risk of gynecologic malignancies such as ovarian cancer and endometrial cancer, but also adversely affect the patients′ fertility and offspring health. Genetic counseling is a cornerstone of HGCS management, enabling identification of high-risk individuals through family pedigree analysis, risk stratification assessments and interpretation of genetic testing results, thereby facilitating the development of personalized intervention strategies incorporating screening and prevention measures. This approach has been proven to reduce the incidence and specific mortality rates of related cancers. The Gynecologic Oncology Society of the Chinese Medical Association has organized experts to compile the Guidelines for Genetic Counseling in Gynecologic Oncology(2025 Edition), which summarizes the pathogenic gene profiles, risk assessment models, and detection strategies for the common HGCS, aiming to standardize the clinical practice of genetic counseling for gynecologic oncology in China. This paper provides a clinical interpretation of the guidelines to improve the accessibility and standardization of genetic counseling services for gynecologic oncology in China.]]> 2026/8/31 10:07:33 Huang Yiqin, Long Xingtao, Zou Dongling 4true ［Abstract］　Objective　To explore the expression characteristics and potential biological functions of dehydrogenase/reductase 9(DHRS9) in serous ovarian carcinoma(SOC), and to analyze its relationship with patient prognosis, SOC cell proliferation, invasion and migration as well as drug sensitivity, so as to provide a theoretical basis for the diagnosis and individualized treatment of SOC. Methods　The expression of DHRS9 in SOC and its associations with clinical characteristics and patient prognosis were analyzed using data from The Cancer Genome Atlas(TCGA) database and the Genotype-Tissue Expression(GTEx) database. Gene Ontology(GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes(KEGG) enrichment analysis were performed to predict the biological processes and signaling pathways involving DHRS9. The Gene Expression Profiling Interactive Analysis(GEPIA) database was used to analyze the correlation between DHRS9 and immune checkpoints. DHRS9-related single-cell data were analyzed using the Tumor Immune Single-cell Hub(TISCH) database. The predictive value of DHRS9 expression levels for sensitivity to SOC-related drugs was analyzed based on the Genomics of Drug Sensitivity in Cancer(GDSC) database. DHRS9 knockdown experiments were performed on ovarian cancer cell lines OVCAR-3 and SK-OV-3, and the cell proliferation, invasion and migration abilities were assessed. Results　DHRS9 was highly expressed in SOC and was significantly associated with poor prognosis(P<0.05). GO and KEGG enrichment analyses indicated that DHRS9 might be involved in cell proliferation and migration as well as immune-related pathways. The DHRS9 high-expression group exhibited significantly lower half-maximal inhibitory concentration(IC₅₀) values for paclitaxel, cisplatin and gemcitabine than the DHRS9 low-expression group(P<0.05). Furthermore, DHRS9 knockdown significantly inhibited the proliferation, migration, and invasion abilities of OVCAR-3 and SK-OV-3 cells. Conclusion　DHRS9 is highly expressed in SOC and is closely associated with patient prognosis. It may promote the occurrence and progression of SOC by regulating cell proliferation, migration and invasion. DHRS9 has the potential to serve as a biological marker for predicting the efficacy of anti-tumor drugs, which provides a theoretical basis for the development of therapeutic targets for SOC.]]> 2026/8/31 0:00:00 Wang Nannan, Tong Xu, Sun Fusheng, Zhang Yongjian 3true ［Abstract］　Objective　To analyze the clinical and pathological features of patients with cervical clear cell adenocarcinoma(CCAC), aiming to provide evidence-based reference for the clinical diagnosis and treatment of this rare tumor. Methods　A retrospective analysis was conducted on the clinical manifestations, histological features, immunohistochemical results, treatment regimens and prognoses of 9 patients with CCAC who were diagnosed and treated at Gansu Provincial Maternity and Child-Care Hospital(Gansu Provincial Central Hospital) from January 2020 to March 2023. Results　The median age of the 9 patients was 64.0 years. Their clinical presentations included postmenopausal vaginal bleeding in 6 patients, contact bleeding in 2 patients, and vaginal bleeding following subtotal hysterectomy for uterine fibroids in 1 patient. Human papillomavirus(HPV) testing was negative in 8 patients. The International Federation of Gynecology and Obstetrics(FIGO) stages of the 9 patients were as follows: stage ⅠB2 in 4 patients, stage ⅡA1 in 2 patients, stage ⅡA2 in 1 patient, stage ⅢC1p in 1 patient, and stage ⅢC2r in 1 patient. Among the 9 patients, 8 patients underwent surgical treatment, and 1 patient with FIGO stage ⅢC2r received chemoradiotherapy without surgery. Seven patients underwent abdominal radical hysterectomy+bilateral salpingo-oophorectomy+pelvic lymphadenectomy, among whom 2 also underwent para-aortic lymphadenectomy and 1 also underwent omentectomy. One patient who had previously undergone subtotal hysterectomy received abdominal radical trachelectomy+bilateral salpingo-oophorectomy+pelvic lymphadenectomy+para-aortic lymphadenectomy. Immunohistochemical results: among the 9 patients tested, 8 were positive for p16(8/9); among the 5 patients tested, all 5 were positive for paired box 8(PAX8)(5/5); among the 8 patients tested, 5 were positive for aspartic proteinase A(Napsin A)(5/8); and among the 5 patients tested, all 5 were positive for hepatocyte nuclear factor-1 beta(HNF-1β)(5/5). The median follow-up period was 25 months, with overall survival(OS) ranging from 16 to 52 months. Conclusion　This study suggests that CCAC predominantly occurs in middle-aged and elderly populations, and that CCAC is not significantly associated with HPV infection. The clinical features of CCAC lack specificity, and there are currently no effective screening methods for CCAC. Further in-depth studies are warranted to improve the prognosis of CCAC.]]> 2026/8/31 10:07:33 1, Wei Ying¹, Zhang Yaqing¹, Zhang Dengcai², Tuo Shumei¹, Wang Li³, Zhou Haiyan¹, Lu Yongli¹, Liu Haiyan¹, Lu Yun¹, Liu Qing¹, Dang Yun^1,4]]> Wan Tao¹, Wei Ying¹, Zhang Yaqing¹, Zhang Dengcai², Tuo Shumei¹, Wang Li³, Zhou Haiyan¹, Lu Yongli¹, Liu Haiyan¹, Lu Yun¹, Liu Qing¹, Dang Yun^1,4 2true ［Abstract］　Objective　To investigate the safety of a modified ureteric tunnel dissection technique in abdominal radical hysterectomy for cervical cancer, and its clinical value in reducing postoperative urinary tract complications. Methods　A retrospective analysis was conducted on the clinical data of 102 patients with cervical cancer who underwent abdominal radical hysterectomy in the First Affiliated Hospital of University of Science and Technology of China(Anhui Provincial Hospital) between January 1, 2021, and July 31, 2022. The patients were divided into a conventional technique group(n=50) and a modified technique group(n=52) based on different methods used for ureteric tunnel dissection during surgery. The perioperative indicators were compared between the two groups, including operative duration, intraoperative blood loss, surgical margins, and postoperative urinary tract complications. Results　Successful operations were performed on all patients in both groups. The operative duration in the modified technique group was shorter than that in the conventional technique group［157.00(141.75, 175.00)min vs 174.00(155.25, 197.50)min］, and the intraoperative blood loss in the modified technique group was less than that in the conventional technique group［200.00(200.00, 300.00)mL vs 300.00(200.00, 400.00)mL］, with statistically significant differences between the two groups(P<0.05). Postoperative pathology revealed no tumor involvement in either the vaginal margins or the parametrial margins in the two groups, indicating an R0 resection. The incidence of postoperative urinary tract complications in the modified technique group was lower than that in the conventional technique group(19.23% vs 40.00%; P=0.030). Conclusion　The modified ureteric tunnel dissection technique demonstrates good safety in abdominal radical hysterectomy for cervical cancer. The technique can significantly reduce intraoperative blood loss and shorten operative duration, and has considerable value for clinical application.]]> 2026/8/31 0:00:00 Lu Xiaofei, Chen Yao, Xia Bairong 1true